Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02 · 8-K

Chrome Holding Co.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on March 23, 2025, Chrome Holding Co.…

Filed Aug 22, 2025Accepted Aug 22, 2025, 12:05 PM EDTCIK 1804591Accession 0001193125-25-186416
Share

Company context

23andMe is a genetics-led consumer healthcare company empowering a healthier future. For more information, please visit www.23andme.com.

Historical securities (5)

Recent company filings

  1. 15-12G filingDec 4, 2025
  2. Bankruptcy or ReceivershipDec 4, 2025
  3. Other EventsNov 17, 2025
  4. NT 10-Q filingNov 7, 2025
  5. Regulation FD DisclosureNov 4, 2025

Disclosure sections

Items 5.02

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on March 23, 2025, Chrome Holding Co. (formerly known as 23andMe Holding Co.), a Delaware corporation (the “Company”), and certain of its subsidiaries (together with the Company, the “Debtors”) filed voluntary petitions seeking relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Eastern District of Missouri (the “Court”). As previously disclosed, on July 14, 2025, the Company and 23andMe Research Institute (formerly known as TTAM Research Institute), a California nonprofit public benefit corporation (“Research Institute”), consummated the transactions contemplated by that certain Asset Purchase Agreement, by and among the Debtors and Research Institute, dated as of June 13, 2025, whereby Research Institute acquired substantially all of the Debtors’ assets (the “Transaction”). Following the consummation of the Transaction, effective August 16, 2025, Research Institute appointed Joseph Selsavage, the Company’s Interim Chief Executive Officer and Chief Financial and Accounting Officer (the “CEO/CFAO”), as its Chief Financial Officer. Mr. Selsavage will continue to serve as the Company’s CEO/CFAO while serving as Research Institute’s Chief Financial Officer (the “Dual Service”) until the effective date of a Court-approved Chapter 11 plan or such later date as may be agreed among the Company and Mr. Selsavage (the “End Date”). On August 21, 2025 (the “Effective Date” and, the period beginning on the Effective Date and ending on the End Date, the “Transition Period”), the Special Committee (the “Committee”) of the Board of Directors of the Company approved certain changes to Mr. Selsavage’s compensation in connection with the Dual Service. Specifically, during the Transition Period, Mr. Selsavage will be entitled to receive 75% of his current annual base salary rate of $600,000 for his service as the CEO/CFAO of the Company. On the Effective Date, the Committee also approved changing Mr. Selsavage’s title from “Interim Chief Executive Officer and Chief Financial and Accounting Officer” to “Chief Executive Officer and Chief Financial and Accounting Officer.”

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.